Results 21 to 30 of about 847 (163)

Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial [PDF]

The Journal of Headache and Pain
Background Atogepant is an oral calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of migraine in adults. These analyses evaluated the proportions of clinical trial participants who experienced sustained responses ...
Richard B. Lipton, Stephanie J. Nahas, Patricia Pozo-Rosich, Tanya Bilchik, Peter McAllister, Michelle Finnegan, Yingyi Liu, Natty Chalermpalanupap, Brett Dabruzzo, David W. Dodick   +9 more
doaj   +5 more sources

Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine [PDF]

CPT: Pharmacometrics & Systems Pharmacology
This work aimed to develop an appropriate model to evaluate the exposure–response relationship (ERR) for monthly migraine days (MMD) in atogepant's key migraine prevention clinical trials to support dose selection. The ERR between atogepant concentration
Louisa Schlachter, Denise Beck, Ramesh R. Boinpally, Sven Stodtmann   +3 more
doaj   +2 more sources

Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review

Pain and Therapy
Introduction Combination use of atogepant and onabotulinumtoxinA has the potential to be more effective than either alone for the preventive treatment of chronic migraine (CM) due to their complementary mechanisms of action.
Andrew M. Blumenfeld, Laszlo Mechtler, Lisa Cook, Christopher Rhyne, Brian Jenkins, Olivia Hughes, Brett Dabruzzo, Aubrey Manack Adams, Merle Diamond   +8 more
doaj   +2 more sources

Small-molecule CGRP antagonist atogepant does not affect cortical spreading depression susceptibility in rats [PDF]

The Journal of Headache and Pain
Background Atogepant is a small-molecule non-competitive calcitonin gene-related peptide (CGRP) receptor antagonist efficacious in preventing episodic migraine.
Xuyan Jin, Andreia Morais, Yuichi Sasaki, Qingling Zhai, Pradeep Banerjee, Andrea Harriott, Cenk Ayata   +6 more
doaj   +2 more sources

“The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials” [PDF]

BMC Neurology
Background Migraine is a complex neurological disorder characterized by recurrent, disabling headaches and various sensory symptoms, affecting about 15% of the global population annually.
Ayesha Shaukat, Laiba Shakeel, Rumaisa Riaz, Saad Ashraf, Aymar Akilimali   +4 more
doaj   +2 more sources

Gepants: targeting the CGRP pathway for migraine relief [PDF]

Frontiers in Pharmacology
BackgroundCalcitonin gene–related peptide (CGRP) receptor antagonist (collectively known as gepant) have emerged as effective therapies for both acute migraine treatment and preventive management.
Bernadetta Jakubowska, Magdalena Sowa-Kućma, Magdalena Sowa-Kućma   +2 more
doaj   +2 more sources

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations [PDF]

Therapeutics and Clinical Risk Management, 2022
Fred Cohen, Hsiangkuo Yuan Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, 19107, USACorrespondence: Hsiangkuo Yuan, Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, 900 ...
Cohen F, Yuan H
doaj   +2 more sources

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study [PDF]

The Journal of Headache and Pain
Background Real-world evidence on atogepant remains limited. GIANT2 explores the 24-week real-life effectiveness of atogepant in patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) under routine clinical conditions.
Piero Barbanti, Gabriella Egeo, Alberto Doretti, Francesca Pistoia, Steno Rinalduzzi, Silvia Strumia, Cinzia Aurilia, Paola Scatena, Massimo Autunno, Antonio Salerno, Alberto Galli, Riccardo Altavilla, Stefano Messina, Carla Zanferrari, Pietrantonio Bruno, Cecilia Camarda, Florindo D’Onofrio, Veronica Iovene, Angelo Ranieri, Francesco Bono, Jesuély Spieckert de Souza, Antonio Carnevale, Laura Di Clemente, Maurizio Zucco, Monica Laura Bandettini Di Poggio, Luisa Vinciguerra, Laura Borrello, Giulia Fiorentini, Rosario Vecchio, Valeria Drago, Paola Torelli, Maria Albanese, Carlo Tomino, Stefano Bonassi, Annamaria Porreca, for the Italian Migraine Registry (I-GRAINE) study group   +35 more
doaj   +2 more sources

Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis

The Journal of Headache and Pain
Background Migraine is one of the most common diseases worldwide while current treatment options are not ideal. New therapeutic classes of migraine, the calcitonin gene-related peptide (CGRP) antagonists, have been developed and shown considerable ...
Min Hou, Xiaofeng Luo, Shuangshuang He, Xue Yang, Qing Zhang, Meihua Jin, Pan Zhang, Yang Li, Xiaoting Bi, Juan Li, Caiyi Cheng, Qiang Xue, Haiyan Xing, Yao Liu   +13 more
doaj   +2 more sources

Variant angina associated with a CGRP receptor antagonist: a case report [PDF]

BMC Neurology
Background Calcitonin gene-related peptide (CGRP) plays a pivotal role in migraine pathophysiology, and CGRP receptor antagonists are increasingly used for acute and preventive treatment.
Hongki Jeon, Jin-Man Cho
doaj   +2 more sources